印度混合接种研究中两剂和三剂腺病毒载体疫苗ChAdOx1 nCov-19与全病毒灭活疫苗BBV152免疫应答的特征分析
该研究在4期随机试验中分析既往接种两剂ChAd或BBV152者分别以ChAd或BBV152加强后的免疫应答,发现无论基础疫苗为何,ChAd加强者的记忆B细胞频率和抗刺突IgG水平均高于BBV152加强者,且接种后180天抗体水平以组4最低。
要点
- 两剂BBV152基础免疫者的记忆B细胞和产细胞因子CD8-T细胞中位数高于ChAd基础者,而抗刺突IgG较低。
- 无论基础疫苗为何,ChAd加强者的记忆B细胞频率和抗刺突IgG水平均高于BBV152加强者。
- 对Omicron及其亚变异株的ACE-2抑制百分比在组3中位数>60%,高于其他组的中位数<25%。
核心结论
- 无论基础免疫方案为何,使用ChAd加强可获得对SARS-CoV-2的持续体液免疫和稳健的细胞免疫应答。
研究设计与样本
- 该研究为4期随机试验中采集样本的免疫学分析,参与者既往接种两剂ChAd或BBV152后随机接受ChAd或BBV152加强,分为4组。
- 亚组参与者中ChAd受者n=37、BBV152受者n=36,在加强前(第二剂后12-36周)和加强后28天检测细胞和体液应答。
- 加强后180天对整个队列(N=378)评估体液应答。
- 试验注册号为ISRTCN(CTRI/2021/08/035648)。
主要发现
- 两剂BBV152基础免疫者较ChAd基础者记忆B细胞中位数更高(0.41% vs 0.35%)、产细胞因子CD8-T细胞中位数更高(0.09% vs 0.04%),而抗刺突IgG中位数更低(12,433 AU/ml vs 27,074 AU/ml)。
- 无论基础疫苗为何,ChAd加强者的记忆B细胞频率和抗刺突IgG水平均高于BBV152加强者。
- 对Omicron及其亚变异株的ACE-2抑制百分比在组3中位数>60%,高于其他组的中位数<25%。
- 加强后180天抗体水平排序为组1∼组2∼组3>组4。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infections with SARS-CoV-2 variants and declining immunity after primary vaccination, encouraged the use of booster doses. Some countries changed their immunization programmes to boost with vaccines different from the ones in their original schedule, based on results from immunogenicity and effectiveness studies. This study reports immunological analysis of samples collected in a phase 4 randomized trial, where participants who had previously received two primary doses of ChAdOx1 nCov-19 (ChAd) or inactivated BBV152 vaccine were randomized to receive either ChAd or BBV152 booster and further categorized as: Group 1 (two primary doses of ChAd - ChAd booster), Group 2 (two primary doses of ChAd - BBV152 booster), Group 3 (two primary doses of BBV152 - ChAd booster), and Group 4 (two primary doses of BBV152 - BBV152 booster). SARS-CoV-2 specific cellular and humoral responses at day 0 (pre-boost samples 12-36 weeks after the second primary dose), and at day 28 post booster, were measured in a subset of participants (ChAd recipients, n = 37 and BBV152 recipients, n = 36). Additionally, on day180 post-booster humoral responses were assessed for the entire cohort (N = 378). Primary vaccination with 2 doses of BBV152 generated higher memory-B cells (median% 0.41 vs 0.35) and cytokine producing CD8-Tcells (median% 0.09 vs 0.04) while lower anti-spike IgG levels (medianAU/ml: 12,433 vs 27,074) as compared to ChAd. Irrespective of the primary vaccine received, ChAd boosted individuals generated higher memory-B cell frequencies and anti-spike IgG levels as compared to BBV152 booster. The percentage ACE-2 inhibition against Omicron and its sub-variants was higher in Group 3 (median > 60 %) as compared to other groups (median < 25 %). At day180 post booster the hierarchy of the antibody amounts was Group 1 ∼ Group 2 ∼ Group 3 > Group 4. Sustained humoral and robust cellular immune response to SARS-CoV-2 can be obtained with ChAd booster irrespective of the primary vaccination regimen. The trial is registered with ISRTCN (CTRI/2021/08/035648).
引用
- Chaudhary A, Madhavan R, Babji S, et al. Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India. Vaccine. 2023. PMID: 37357073. doi:10.1016/j.vaccine.2023.06.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。